Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Pharmacology

Background:

• Clofarabine is an established chemotherapeutic agent for pediatric leukemia.
• Previous studies have documented various adverse effects associated with clofarabine treatment in children.
• Refractory acute lymphoblastic leukemia (ALL) presents a significant therapeutic challenge in pediatric oncology.

Observation:

• A pediatric patient with refractory acute lymphoblastic leukemia was treated with clofarabine.
• The patient developed symptoms consistent with capillary leak syndrome during the course of clofarabine therapy.
• Capillary leak syndrome is a serious condition characterized by plasma leakage from blood vessels.

Findings:

• The patient experienced a fatal outcome due to the development of capillary leak syndrome.
• This case underscores a rare but severe adverse event associated with clofarabine in a pediatric patient.
• The clinical presentation and rapid progression of capillary leak syndrome were noted.

Implications:

• Clinicians should maintain a high index of suspicion for capillary leak syndrome in children receiving clofarabine.
• Early recognition and management of capillary leak syndrome may be critical for improving patient outcomes.
• Further research into the mechanisms and risk factors for clofarabine-induced capillary leak syndrome is warranted.